SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Apophis
Search This Board: 
Last Post: 10/19/2017 9:46:07 PM - Followers: 122 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 

Company website: 
http://www.aveooncology.com/

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

   





Product pipeline candidates include Tivozanib, Ficlatuzumab, AV-203, AV-353 and AV-380.
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO aveobd@aveooncology.com to discuss partnership opportunities with AVEO’s development pipeline.

European Medicines Agency (EMA), has approved on 8/28/17  FOTIVDA™ (tivozanib) for approval as a treatment (Solid Dose) for patients with advanced renal cell carcinoma (RCC)
 

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.

AV-353

AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including cancer, cardiovascular diseases and neurodegenerative conditions. Publications, including Nature Medicine (2009), have implicated the Notch 3 pathway in Pulmonary Arterial Hypertension (PAH). PAH is a rare and life-threatening disorder that affects approximately 250,000 people worldwide and is caused by enlargement of the arterial walls in small arteries between the heart and the lungs, resulting in restricted blood flow.

Current treatments in PAH focus only on controlling symptoms by avoiding vasoconstriction and increasing vasodilation of vessels and do not reverse the underlying cause of the disease. In contrast, with the results of a recently concluded preclinical animal studies supported by AVEO, AV-353 has generated a growing body of preclinical data that supports AV-353’s ability to potentially reverse the disease phenotype, which would represent a potential disease-modifying approach to treatment. AVEO is currently seeking a partner to develop and commercialize AV-353 worldwide in PAH.

For additional information, or to inquire about potential partnering opportunities, please contact Nikhil Mutyal (nmutyal@aveooncology.com).

 
www.aveopharma.com
Shares Outstanding   110,363,000
Insider Ownership 17%
Institutional + Mutual Fund Ownership  58%
20 Full Time Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: ir@aveooncology.com

 
SureTrader
Interactive Brokers Advertisement
AVEO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO News: AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium 10/16/2017 07:00:00 AM
AVEO News: AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol 10/05/2017 05:30:00 PM
AVEO News: AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in 09/20/2017 07:10:00 AM
AVEO News: AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge 09/13/2017 07:00:00 AM
AVEO News: AVEO Oncology to Present at Upcoming Conferences 09/05/2017 07:00:00 AM
PostSubject
#3087  Sticky Note AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the Maple tree 08/28/17 06:46:30 AM
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#3401   Screw off goofball tonypro99 10/19/17 09:46:07 PM
#3400   Pretty decent buys AH Bullwinkle77 10/19/17 05:47:44 PM
#3399   those pests are the same ones shorting it, harry crumb 10/19/17 05:07:19 PM
#3398   its clay's shorties who will get fried! just harry crumb 10/19/17 05:05:47 PM
#3397   * * $AVEO Video Chart 10-19-17 * * ClayTrader 10/19/17 04:35:20 PM
#3396   Ughhhh I slept through market open and did bigl0u 10/19/17 03:52:18 PM
#3395   hey clay, yur group of shorties are going harry crumb 10/19/17 08:25:02 AM
#3394   * * $AVEO Video Chart 10-18-17 * * ClayTrader 10/18/17 04:50:50 PM
#3393   agree, patience! $$$ harry crumb 10/18/17 02:31:33 PM
#3392   Good riddance if it weeds the traders out. twistedfreak 10/18/17 11:09:21 AM
#3391   Time for a 7:1 reverse if these short Apophis 10/18/17 09:17:43 AM
#3390   That drop caused a lot of folks to Apophis 10/18/17 09:04:58 AM
#3389   It did not take much volume to drop Apophis 10/18/17 08:52:09 AM
#3388   huge short attack! i hav been telling people harry crumb 10/17/17 10:49:07 PM
#3387   * * $AVEO Video Chart 10-17-17 * * ClayTrader 10/17/17 04:50:39 PM
#3386   aveo is still a 4+ pps stock with harry crumb 10/17/17 03:33:36 PM
#3385   Massive buying opportunity bigl0u 10/17/17 03:11:20 PM
#3384   This is a sham or one helluva buying opportunity!!!!!????!!! Beerworld 10/17/17 02:51:26 PM
#3383   Only 400,000 shares separate the buy and sells. Apophis 10/17/17 11:48:16 AM
#3382   this could be a well orchestrated short attack harry crumb 10/17/17 10:45:14 AM
#3381   loading the boat! $$$ harry crumb 10/17/17 10:27:09 AM
#3380   PM does not make sense as it is Apophis 10/17/17 09:18:55 AM
#3379   3.30's today possible harry crumb 10/17/17 09:03:44 AM
#3378   SEC filings. twistedfreak 10/16/17 05:42:04 PM
#3377   Where can that be found? justradin 10/16/17 04:14:14 PM
#3376   everything taking a beating, including aveo, i said harry crumb 10/16/17 04:03:53 PM
#3375   Agree. Whole segment is down hard today. Anyone twistedfreak 10/16/17 03:54:37 PM
#3374   Big sell off today in biotech might be Apophis 10/16/17 01:30:09 PM
#3373   Bailey has to have a card up his twistedfreak 10/16/17 12:22:51 PM
#3372   SEE IF THE MM's LET THIS THING MOVE Apophis 10/16/17 09:45:38 AM
#3371   AVEO Oncology Announces Phase 1 Results from TiNivo ProfitScout 10/16/17 09:31:29 AM
#3370   I did , check idra and ipix 2 youssef 10/13/17 07:12:09 AM
#3369   yeah, i could see that 17.50-20.00 range very possible harry crumb 10/12/17 10:49:50 PM
#3368   maybe some decent sales in the EU, or harry crumb 10/12/17 10:48:34 PM
#3367   I agree, I just read something like that Apophis 10/12/17 07:24:10 AM
#3366   With Tivo approved in Europe and an ongoing twistedfreak 10/12/17 06:53:50 AM
#3365   I don t see 3 billions buy out youssef 10/12/17 03:23:32 AM
#3364   A buy out right now conservatively at Apophis 10/11/17 08:27:26 PM
#3363   Maybe once we see some sales results out Apophis 10/11/17 08:13:58 PM
#3362   When we going to close at a new Apophis 10/11/17 08:03:55 PM
#3361   all those tiny trades that were sells at harry crumb 10/10/17 04:36:53 PM
#3360   back in july there were a few stock harry crumb 10/10/17 11:51:25 AM
#3359   it is a scary thing that insiders are harry crumb 10/10/17 11:49:49 AM
#3358   minor, nice rebound. harry crumb 10/09/17 09:37:10 PM
#3357   The selloff continues. Apophis 10/09/17 10:37:40 AM
#3356   https://www.stockscores.com/charts/charts/?ticker=aveo mick 10/08/17 12:35:40 PM
#3355   Correct. People were expecting a bump from the twistedfreak 10/06/17 01:30:16 PM
#3354   Thanks for the reply justradin 10/06/17 01:21:53 PM
#3353   Oh ok, I thought I missed something else. justradin 10/06/17 01:21:29 PM
#3352   the positive phase 3 Futility Analysis for Tivo twistedfreak 10/06/17 01:16:52 PM
PostSubject